Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells

British Journal of Cancer

Volumn 107, Issue 9, 2012, Pages 1488-1497

  Liu, P ^a   Brown, S ^a   Goktug, T ^a   Channathodiyil, P ^a   Kannappan, V ^a   Hugnot, J P ^b   Guichet, P O ^b   Bian, X ^c   Armesilla, A L ^a   Darling, J L ^a   Wang, W ^a  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^b Montpellier University Medical Center   (France)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

copper; disulfiram; GBM stem like cells; gemcitabine; NFkB; reactive oxygen species

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALDEHYDE DEHYDROGENASE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; COPPER; DISULFIRAM; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; SYNAPTOPHYSIN;

ARTICLE; BLOOD BRAIN BARRIER; CANCER STEM CELL; CELL ASSAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; ELECTROPHORETIC MOBILITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; PRIORITY JOURNAL; PROTEIN FUNCTION; WESTERN BLOTTING;

ALDEHYDE DEHYDROGENASE; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; COPPER; CYTOTOXICITY, IMMUNOLOGIC; DEOXYCYTIDINE; DISULFIRAM; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; NEOPLASTIC STEM CELLS; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; REACTIVE OXYGEN SPECIES;

EID: 84867897977     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.442     Document Type: Article

References (50)

1. Barceloux DG (1999) Copper. J Toxicol Clin Toxicol 37: 217-230
2. Bergman AM, Pinedo HM, Peters GJ (2002) Determinants of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5: 19-33
3. Bodenner DL, Dedon PC, Keng PC, Katz JC, Borch RF (1986) Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate. Cancer Res 46: 2751-2755
4. Burkitt MJ, Bishop HS, Milne L, Tsang SY, Provan GJ, Nobel CS, Orrenius S, Slater AF (1998) Dithiocarbamate toxicity toward thymocytes involves their copper-catalyzed conversion to thiuram disulfides, which oxidize glutathione in a redox cycle without the release of reactive oxygen species. Arch Biochem Biophys 353: 73-84
5. Cen D, Brayton D, Shahandeh B, Meyskens Jr FL, Farmer PJ (2004) Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem 47: 6914-6920
6. Cen D, Gonzalez RI, Buckmeier JA, Kahlon RS, Tohidian NB, Meyskens Jr FL (2002) Disulfiram induces apoptosis in human melanoma cells: a redox-related process. Mol Cancer Ther 1: 197-204
7. Chen D, Cui QC, Yang H, Dou QP (2006) Disulfiram, a clinically used antialcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 66: 10425-10433
8. Chong CR, Sullivan Jr DJ (2007) New uses for old drugs. Nature 448: 645-646
9. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55
10. Conticello C, Martinetti D, Adamo L, Buccheri S, Giuffrida R, Parrinello N, Lombardo L, Anastasi G, Amato G, Cavalli M, Chiarenza A, De Maria R, Giustolisi R, Gulisano M, Di Raimondo F (2012) Disulfiram, an old drug with new potential therapeutic uses for human haematological malignancies. Int J Cancer 131: 2197-2203
11. Croker AK, Allan AL (2011) Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDH(hi)CD44 (+) human breast cancer cells. Breast Cancer Res Treat 133: 75-87
12. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458: 780-783
13. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-185
14. Eneanya DI, Bianchine JR, Duran DO, Andresen BD (1981) The actions of metabolic fate of disulfiram. Annu Rev Pharmacol Toxicol 21: 575-596
15. Estey T, Piatigorsky J, Lassen N, Vasiliou V (2007) ALDH3A1: a corneal crystallin with diverse functions. Exp Eye Res 84: 3-12
16. Fruehauf JP, Meyskens Jr FL (2007) Reactive oxygen species: a breath of life or death? Clin Cancer Res 13: 789-794
17. Gertler SZ, MacDonald D, Goodyear M, Forsyth P, Stewart DJ, Belanger K, Perry J, Fulton D, Steward W, Wainman N, Seymour L (2000) NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94). Ann Oncol 11: 315-318
18. Gloire G, Legrand-Poels S, Piette J (2006) NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72: 1493-1505
19. Gunasekaran S, Weinstein P, Anderson G, Parker D, Misiorowski RL, Chvapil M (1983) Distribution of disulfiram in brain after carotid ligation in gerbils. Neuropharmacology 22: 1159-1163
20. Guo X, Xu B, Pandey S, Goessl E, Brown J, Armesilla AL, Darling JL, Wang W (2010) Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. Cancer Lett 291: 104-113
21. Gupte A, Mumper RJ (2009) Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 35: 32-46
22. Hacker MP, Ershler WB, Newman RA, Gamelli RL (1982) Effect of disulfiram (tetraethylthiuram disulfide) amd diethyldithiocarbamate on the bladder toxicity and antitumor activity of cyclophosphamide in mice. Cancer Res 42: 4490-4494
23. Hieger I (1926) The effect of copper compounds upon the growth of carcinoma in the rat. Biochem J 20: 232-236
24. Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, Grafstrom RC, Perala M, Kallioniemi O (2009) High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res 15: 6070-6078
25. Jean E, Laoudj-Chenivesse D, Notarnicola C, Rouger K, Serratrice N, Bonnieu A, Gay S, Bacou F, Duret C, Carnac G (2011) Aldehyde dehydrogenase activity promotes survival of human muscle precursor cells. J Cell Mol Med 15: 119-133
26. Johansson B (1992) A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 369: 15-26
27. Junttila MR, Li SP, Westermarck J (2008) Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 22: 954-965
28. Kim BE, Nevitt T, Thiele DJ (2008) Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol 4: 176-185
29. Landen Jr CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast Jr RC, Coleman RL, Lopez-Berestein G, Sood AK (2010) Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 9: 3186-3199
30. Lipsky JJ, Shen ML, Naylor S (2001) Overview-in vitro inhibition of aldehyde dehydrogenase by disulfiram and metabolites. Chem Biol Interact 130-132: 81-91
31. Lopez-Lazaro M (2007) Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. Cancer Lett 252: 1-8
32. Margalioth EJ, Schenker JG, Chevion M (1983) Copper and zinc levels in normal and malignant tissues. Cancer 52: 868-872
33. McCubrey JA, Lahair MM, Franklin RA (2006) Reactive oxygen speciesinduced activation of the MAP kinase signaling pathways. Antioxid Redox Signal 8: 1775-1789
34. Metro G, Fabi A, Mirri MA, Vidiri A, Pace A, Carosi M, Russillo M, Maschio M, Giannarelli D, Pellegrini D, Pompili A, Cognetti F, Carapella CM (2010) Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. Cancer Chemother Pharmacol 65: 391-397
35. Moreb JS, Baker HV, Chang LJ, Amaya M, Lopez MC, Ostmark B, Chou W (2008) ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol Cancer 7: 87
36. Moreb JS, Ucar D, Han S, Amory JK, Goldstein AS, Ostmark B, Chang LJ (2011) The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chem Biol Interact 195: 52-60
37. Muzio G, Maggiora M, Paiuzzi E, Oraldi M, Canuto RA (2012) Aldehyde dehydrogenases and cell proliferation. Free Radic Biol Med 52: 735-746
38. Nakano H, Nakajima A, Sakon-Komazawa S, Piao JH, Xue X, Okumura K (2006) Reactive oxygen species mediate crosstalk between NF-kappaB and JNK. Cell Death Differ 13: 730-737
39. Pappa A, Brown D, Koutalos Y, DeGregori J, White C, Vasiliou V (2005) Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells. J Biol Chem 280: 27998-28006
40. Rayet B, Gelinas C (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18: 6938-6947
41. Reardon DA, Rich JN, Friedman HS, Bigner DD (2006) Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24: 1253-1265
42. Robe PA, Martin DH, Nguyen-Khac MT, Artesi M, Deprez M, Albert A, Vanbelle S, Califice S, Bredel M, Bours V (2009) Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer 9: 372
43. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401
44. Vescovi AL, Galli R, Reynolds BA (2006) Brain tumour stem cells. Nat Rev Cancer 6: 425-436
45. Veverka KA, Johnson KL, Mays DC, Lipsky JJ, Naylor S (1997) Inhibition of aldehyde dehydrogenase by disulfiram and its metabolite methyl diethylthiocarbamoyl-sulfoxide. Biochem Pharmacol 53: 511-518
46. Wang W, Cassidy J, O'Brien V, Ryan KM, Collie-Duguid E (2004) Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells. Cancer Res 64: 8167-8176
47. Wang W, McLeod HL, Cassidy J (2003) Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 104: 504-511
48. Ye XQ, Li Q, Wang GH, Sun FF, Huang GJ, Bian XW, Yu SC, Qian GS (2011) Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. Int J Cancer 129: 820-831
49. Yip NC, Fombon IS, Liu P, Brown S, Kannappan V, Armesilla AL, Xu B, Cassidy J, Darling JL, Wang W (2011) Disulfiram modulated ROS-MAPK and NFkB pathways and targeted breast cancer cells with cancer stem cell like properties. Br J Cancer 104: 1564-1574
50. Yoshida D, Ikeda Y, Nakazawa S (1993) Quantitative analysis of copper, zinc and copper/zinc ratio in selected human brain tumours. J Neurooncol 16: 109-115